Compare Upwork Inc (UPWK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Upwork Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Upwork Inc trades at $8.24 (market cap $1.04B), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 128.9× Upwork Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| UPWK | VRTX | |
|---|---|---|
Market Cap | $1.04B | $134.06B |
Sector | Industrials | Health |
52-Week High | $22.11 | $557.96 |
52-Week Low | $7.84 | $376.62 |
Enterprise Value | $802.40M | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Upwork (UPWK) is trading at $8.32, down 5.35% on the day, with a bearish technical signal and recent earnings volatility. The company maintains strong profitability metrics including a 77.21% gross margin and 12.93% net income margin, though Q2 2026 earnings beat was overshadowed by weak guidance. Recent news highlights multiple securities fraud investigations alongside AI integration developments.
The stock presents a mixed outlook with attractive valuation multiples (P/E 10.67, P/S 1.44) but faces headwinds from AI disruption and legal scrutiny. Analyst consensus leans bullish with a $9.00 price target, though technical indicators suggest near-term pressure with support at $8.00.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
